The burden of cancer in Europe and the availability of cancer drugs

EJHP Practice

Volumn 15, Issue 4, 2009, Pages 20-23

  Stark, Craig G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; ECONOMIC ASPECT; EUROPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; LUNG CANCER; MELANOMA; PROSTATE CANCER; STOMACH CANCER; SURVIVAL RATE; UTERUS CANCER;

EID: 70349616818     PISSN: 17819989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wilking N, Jönsson, B. Comparator Report on Patient Access to Cancer Drugs in Europe, 2009, Karolinska Institutet and Stockholm School of Economics: Stockholm. www.comparatorreports.se.
2. Jönsson B, Wilking N. Apan-European comparison regarding patient access to cancer drugs. 2005, Karolinska Institutet and Stockholm School of Economics: Stockholm.
3. Jönsson B, Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007;18(Suppl 3):iii1-77.
4. Jönsson B, Lichtenberg F, Wilking N. Reply to 'Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol. 2007;18(Suppl 3): 1-75).
5. Michel P Coleman. Ann Oncol. 2007;18(9):1585-1587.
6. Ferlay J, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581-592. (Pubitemid 46359643)
7. Ferlay J, Bray F, Pisani P, Parkin, DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. Version 2.0. IARC Press, 2004.
8. Schroder FH. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Can J Urol. 2005;12(Suppl 1):2-6; discussion 92-93.
9. Gutierrez-Ibarluzea I, Asua J, Latorre K. Policies of screening for colorectal cancer in European countries. Int J Technol Assess Health Care. 2008;24(3):270-276.
10. Hackshaw A. EUSOMAreview of mammography screening. Ann Oncol. 2003;14(8):1193-1195.
11. Feig SA. Screening mammography: a successful public health initiative. Rev Panam Salud Publica. 2006;20(2-3):125-133.
12. Verdecchia A, et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE- 4 data. Lancet Oncol. 2007;8(9):784-796.
13. Berrino F, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE- 4 study. Lancet Oncol. 2007; 8(9):773-783.
14. De Pouvourville, G. Risk-sharing agreements for innovative drugs - Anew solution to old problems. Eur J Health Econ. 2006;7(3):155-157.
15. Bosanquet N, Attridge J, Sikora K. Can the new EU members catch up in cancer care? Eurohealth. 2005;11(1).
16. Statistisches Bundesamt, Gesundheit - Krankheitskosten, 2002, 2004 und 2006. 2008, Wiesbaden: Statistisches Bundesamt.
17. Jönsson B. Being NICE is not the problem! Eur J Cancer. 2009;45(7):1100-1102.